

PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

Docket No: Q97365

Akira NAKAGAWARA, et al.

Appln. No.: 10/594,448

Group Art Unit: 1646

Confirmation No.: 1244

Examiner: Unknown

Filed: May 15, 2007

For: METHOD OF SCREENING COMPOUND CAPABLE OF ACCELERATING OR INHIBITING
APOPTOSIS, APOPTOSIS ACCELERATOR AND APOPTOSIS INHIBITOR

INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. §§ 1.97 and 1.98

MAIL STOP AMENDMENT

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure under 37 C.F.R. § 1.56, Applicant hereby notifies the U.S. Patent and Trademark Office of the documents which are listed on the attached PTO/SB/08 A & B (modified) form and/or listed herein and which the Examiner may deem material to patentability of the claims of the above-identified application.

1. WO 03/061710 A1, published July 31, 2003 with English abstract.
2. "Inhibitor of nuclear factor kappa-B kinase subunit alpha", Database UniProt [Online], retrieved from EBI accession no. UNIPROT:015111, Database accession no. 015111, January 1, 1998 (XP002466446).
3. F. Kazushige et al., "Stabilization of p73 by nuclear I kappa B kinase-alpha mediates cisplatin-induced apoptosis", Journal of Biological Chemistry, Vol. 282, No. 25, ISSN:0021-9258, June 2007, pp. 18365-18378, (XP00246445).

One copy of each of the listed documents is submitted herewith.


The present Information Disclosure Statement is being filed: (1) No later than three months from the application's filing date; (2) Before the mailing date of the first Office Action on the merits (whichever is later); or (3) Before the mailing date of the first Office Action after filing a request for continued examination (RCE) under §1.114, and therefore, no Statement under 37 C.F.R. § 1.97(e) or fee under 37 C.F.R. § 1.17(p) is required.

Applicant encloses herewith a copy of a corresponding European Search Report dated February 11, 2008 citing such documents and indicating the degree of relevance found by the foreign patent office.

The submission of the listed documents is not intended as an admission that any such document constitutes prior art against the claims of the present application. Applicant does not waive any right to take any action that would be appropriate to antedate or otherwise remove any listed document as a competent reference against the claims of the present application.

The USPTO is directed and authorized to charge all required fees, except for the Issue Fee and the Publication Fee, to Deposit Account No. 19-4880. Please also credit any overpayments to said Deposit Account.

Respectfully submitted,



John T. Callahan
Registration No. 32,607

SUGHRUE MION, PLLC
Telephone: (202) 293-7060
Facsimile: (202) 293-7860

WASHINGTON OFFICE

23373

CUSTOMER NUMBER

Date: March 28, 2008